Literature DB >> 20089110

Long-term oncological outcome after post-chemotherapy retroperitoneal lymph node dissection in men with metastatic nonseminomatous germ cell tumour.

Aude Fléchon1, Emmanuelle Tavernier, Helen Boyle, Pierre Meeus, Michel Rivoire, Jean-Pierre Droz.   

Abstract

OBJECTIVE: To determine whether conformity to standard recommendations of retroperitoneal lymph node dissection (RPLND) after chemotherapy for testicular and primary retroperitoneal nonseminomatous germ cell tumours (NSGCT) and completeness of surgical excision have an effect on oncological outcome. PATIENTS AND METHODS: This was a retrospective study of patients with testicular and primary retroperitoneal NSGCT, with initial involvement of RPLNs, treated between June 1992 and December 2002 in one institution. We reviewed the clinical, surgical and histological charts of 151 such patients who had a RPLND after first-line platinum-based chemotherapy. The recommendations used to define conformity to RPLND standards were: the indication based on initial and residual lymph node size, shrinkage, extension of dissection and completeness of resection.
RESULTS: RPLND conformed to standard recommendations in 70 of the 151 (46%) patients. Conformity was complete for the surgeon who operated on 48 patients and was 26% of the others. Fifteen patients (10%) relapsed in the retroperitoneum, 14 of whom had initial lymph nodes of > or =5 cm. Two patients (3%) relapsed in the group of 70 patients with conformed and complete RPLND, vs 13 (16%) in the 81 with conformed but incomplete resection or with non-conformed and complete or incomplete RPLND. After a median (range) follow-up of 77 (1.3-186.5) months 132 patients were alive with no evidence of disease, 18 died and one was alive with progressive disease. The limitations of this study were the relatively few patients and that it was retrospective.
CONCLUSION: There was conformity of RLNPD to the recommendations, and completeness of resection, in half of the patients operated; this might have an effect on oncological outcome. Our data suggest that patients should be treated in tertiary centres.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20089110     DOI: 10.1111/j.1464-410X.2009.09175.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  17 in total

Review 1.  [What is new in 2011 regarding testicular cancer].

Authors:  S Krege
Journal:  Urologe A       Date:  2011-09       Impact factor: 0.639

2.  [Comments on retroperitoneal lymphadenectomy - laparoscopic versus robotic].

Authors:  A Heidenreich
Journal:  Urologe A       Date:  2012-05       Impact factor: 0.639

3.  [Update on first-line and relapse chemotherapy for testicular cancer].

Authors:  A Lorch; P Albers
Journal:  Urologe A       Date:  2013-11       Impact factor: 0.639

4.  External validation of the Heidenreich criteria for patient selection for unilateral or bilateral retroperitoneal lymph node dissection for post-chemotherapy residual masses of testicular cancer.

Authors:  Cédric Vallier; Pierre-Henri Savoie; Jean-Robert Delpero; Franck Bladou; Gwenaëlle Gravis; Naji Salem; Dominique Rossi; Jochen Walz
Journal:  World J Urol       Date:  2014-01-20       Impact factor: 4.226

Review 5.  [Diagnosis, treatment and follow-up of testicular cancer].

Authors:  Susanne Krege
Journal:  Urologe A       Date:  2017-12       Impact factor: 0.639

6.  Post-chemotherapy retroperitoneal lymph node dissection in the management of metastatic testis cancer: the 16-year experience in an Irish setting.

Authors:  S Considine; R Heaney; R Conroy; J A Thornhill
Journal:  Ir J Med Sci       Date:  2015-12-21       Impact factor: 1.568

Review 7.  Surgical resection of urological tumor metastases following medical treatment.

Authors:  Axel Heidenreich; Stefan Wilop; Michael Pinkawa; Daniel Porres; David Pfister
Journal:  Dtsch Arztebl Int       Date:  2012-09-28       Impact factor: 5.594

Review 8.  [Limits of surgery in uro-oncology].

Authors:  A Heidenreich
Journal:  Urologe A       Date:  2018-09       Impact factor: 0.639

Review 9.  [Diagnostics and treatment of seminomatous germ cell tumors].

Authors:  F Zengerling; J Müller; S Krege; M Schrader
Journal:  Urologe A       Date:  2014-04       Impact factor: 0.639

10.  [Diagnosis and treatment of nonseminomatous germ cell tumors].

Authors:  S Krege
Journal:  Urologe A       Date:  2013-12       Impact factor: 0.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.